ClinicalTrials.gg
RecruitingNCT06177002PROTEGGIMIUpdated Dec 20, 2023

SARS-CoV-2, TESTOSTERONE AND MALE FRAGILITY

An observational study in COVID-19, Testosterone Deficiency and Infertility, Male, sponsored by IRCCS San Raffaele. Recruiting at 1 site in Italy. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-20.

Sponsored by IRCCS San Raffaele · Observational

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Started May 2020; still recruiting 6 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in COVID-19 by IRCCS San Raffaele — 1 open to participants now, 3 under way, none of them phase 3. COVID-19 · IRCCS San Raffaele.

Planned enrollment
Largest of 10
2,000 · median 400
Started
2020
with 7 others
Observational
10 of 12
1 open now
Registered
9th of 12
by date

Among the 12 studies in COVID-19 by IRCCS San Raffaele, this one has the largest planned enrollment of the 10 observational ones that give a count, is one of 8 that started in 2020, is one of 10 observational ones, and was the 9th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

1 of the 12 studies in COVID-19 by IRCCS San Raffaele is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in COVID-19 by IRCCS San Raffaele, or all of them as a file.
02

Study summary

The hormonal environment (steroid, primarily) could have a very relevant pathophysiological role in association with SARS-CoV-2. That is, testosterone could play a relevant role in leaving male subjects more exposed to infection and more prone to developing severe complications following COVID-19 infection.

Read the detailed description

Preliminary data suggests that male individuals are more susceptible to COVID-19 infection, at least in Western countries, and that their mortality rate is higher than female individuals. This would seem to suggest that the hormonal environment (steroid, primarily) could have a very relevant pathophysiological role in association with SARS-CoV-2. That is, testosterone could play a relevant role in leaving male subjects more exposed to infection and more prone to developing severe complications following COVID-19 infection. Another option is that COVID-19 infection could cause a condition of acute hypogonadism, following which, the exhaustion of androgenic action could act as a co-trigger of a severe or even fatal course of the disease.

03

Conditions studied

  • COVID-19
  • Testosterone Deficiency
  • Infertility, Male
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Male COVID-19 patients and male healthy individuals

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patient Cohort:

  • Male patients with an age > 18 hospitalized in the departments dedicated to the care of patients affected by COVID-19 at the San Raffaele Hospital and with:
  • biological samples positive for SARS-CoV-2;
  • negative test but highly suggestive clinical and radiological picture;
  • patients discharged from the emergency room with biological samples positive for SARS-CoV-2;
  • ability to read and sign the

Control Cohort:

  • healthy donors with an age> 18 accessing the IRCCS OSR Blood Donor Center;
  • ability to read and sign the informed consent

Exclusion criteria

Exclusion Criteria:

  • People with an age \< 18;
  • incapacity to read and sign the
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Male COVID-19 patients

    Male patients with an age \> 18 affected by COVID-19 with biological samples positive for SARS-CoV-2 but with negative test

    Diagnostic Test: Collection of biological data

  • male healthy individuals

    Healthy donors with an age\> 18 accessing the IRCCS OSR Blood Donor Center

    Diagnostic Test: Collection of biological data

Interventions

  • Diagnostic testCollection of biological data

    Biological sample will be collected from the COVID19 patients and from healthy donors

06

What researchers measure

Primary outcomes

  1. Dosage of the androgenic hormonal environment in the blood of patients and healthy controls

    Time frame: Baseline

Secondary outcomes

  1. create an international (European) registry for the management of sensitive data in epidemiological terms and pathology outcomes relating to males with confirmed COVID-19 infection and age-matched healthy controls

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2020 (actual). Primary completion is estimated for May 2025, 59 months after the start.

Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 59 months is above that.

Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2023
First posted
Dec 20, 2023
StartActual
May 19, 2020
Primary completionEst.
May 18, 2025
CompletionEst.
May 18, 2025
Last update
Dec 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06177002
Lead sponsor
IRCCS San Raffaele
Responsible party
Andrea Salonia (Prof, IRCCS San Raffaele) — Principal investigator
First posted
Dec 20, 2023
Start date
May 19, 2020
Primary completion
May 18, 2025 (estimated)
Completion
May 18, 2025 (estimated)
Last update
Dec 20, 2023

Study contacts

Anna Maria Ferrara
Contact
ferrara.annamaria@hsr.it
0226437795

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion